Last updated: August 8, 2026
DynaCirc CR, the extended-release formulation of nisoldipine, is a mature antihypertensive product with limited current commercial significance. Its U.S. regulatory exclusivity and core patent protection expired years ago, generic competition removed most pricing power, and public companies have not reported standalone revenue for the product. The commercial trajectory is best characterized as a long decline from branded calcium-channel-blocker sales to a low-volume generic market.
What is DynaCirc CR and how does it work?
DynaCirc CR is an extended-release oral formulation of nisoldipine, a dihydropyridine calcium-channel blocker approved for the treatment of hypertension. Nisoldipine reduces arterial smooth-muscle contraction by inhibiting calcium influx through L-type calcium channels, lowering peripheral vascular resistance and blood pressure.
The product was designed for once-daily administration. Its extended-release delivery system distinguishes DynaCirc CR from immediate-release nisoldipine products and from other dihydropyridine drugs such as amlodipine, felodipine, nifedipine, and isradipine.
DynaCirc CR product profile
| Attribute |
DynaCirc CR |
| Active ingredient |
Nisoldipine |
| Drug class |
Dihydropyridine calcium-channel blocker |
| Dosage form |
Extended-release tablet |
| Primary indication |
Hypertension |
| U.S. regulatory pathway |
New Drug Application |
| U.S. approval period |
Mid-1990s |
| Typical dosing |
Once daily |
| Current commercial position |
Mature, low-volume product |
| Main competitors |
Amlodipine, felodipine ER, nifedipine ER, generic nisoldipine ER |
| Biosimilar exposure |
None |
| Principal commercial risk |
Generic substitution and low prescribing demand |
The FDA label identifies DynaCirc CR as a controlled-release nisoldipine product for hypertension and describes dose-related adverse reactions including headache, peripheral edema, dizziness, and flushing.[1]
When did DynaCirc CR lose exclusivity?
DynaCirc CR lost meaningful U.S. exclusivity well before the current period. The product is not a protected growth asset.
The original branded approval occurred in an established antihypertensive category where competing calcium-channel blockers had already achieved broad physician adoption. Any regulatory exclusivity attached to the original approval expired decades ago. The product’s commercial defense therefore depended on formulation patents, brand recognition, physician familiarity, and manufacturing economics rather than regulatory exclusivity.
DynaCirc CR exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| Nisoldipine development and branded approval |
1990s |
Established the branded franchise |
| DynaCirc CR extended-release launch |
1990s |
Added once-daily formulation |
| Core regulatory exclusivity expiration |
Late 1990s to early 2000s |
Opened pathway for generic competition |
| Formulation patent expiry |
Early to mid-2000s, depending on patent and jurisdiction |
Reduced barriers to generic extended-release products |
| Generic nisoldipine ER competition |
2000s onward |
Accelerated price and volume erosion |
| Mature generic market |
2010s onward |
Reduced branded revenue and declining commercial relevance |
The exact patent-by-patent exclusivity calculation depends on the relevant U.S. patent family, patent-term adjustments, terminal disclaimers, and Orange Book listing history. No currently material market exclusivity remains associated with DynaCirc CR.
What patents protect DynaCirc CR?
The commercially relevant DynaCirc CR protection historically centered on nisoldipine composition and extended-release formulation technology. Those rights are no longer a meaningful barrier to generic entry.
Publicly available regulatory and patent records do not support treating DynaCirc CR as a product with an active, high-value patent estate. The product’s key differentiation was the controlled-release dosage form, but the age of the product places any original formulation patents well beyond normal pharmaceutical exclusivity periods.
Patent categories historically relevant to DynaCirc CR
Active-ingredient patents
Nisoldipine was protected by early compound and pharmaceutical-composition patents associated with its original development. Those patents expired long ago.
Formulation patents
The extended-release dosage form created a separate layer of potential protection. These patents could cover:
- Controlled release of nisoldipine over a 24-hour dosing interval
- Tablet composition and excipient selection
- Release-rate characteristics
- Dose uniformity and stability
- Manufacturing processes for extended-release tablets
Formulation protection did not preserve long-term pricing power because generic manufacturers could enter after expiration or design around narrow claims.
Method-of-use patents
The principal use, treatment of hypertension, is an established indication. Any original method-of-use rights are expired or commercially irrelevant. There is no known current method-of-use patent position that materially restricts generic prescribing or substitution.
Manufacturing and process protection
Manufacturing know-how may remain proprietary in individual supply chains, but it does not create meaningful market exclusivity where multiple manufacturers can produce nisoldipine extended-release tablets under abbreviated regulatory pathways.
What is the FDA regulatory status of DynaCirc CR?
DynaCirc CR was approved through the FDA's NDA pathway, but its commercial status is that of an old, largely commoditized product. FDA approval of the reference product does not prevent ANDA sponsors from marketing generic nisoldipine extended-release tablets after applicable patents and exclusivities expire.
The FDA Orange Book remains the primary source for determining whether a reference-listed drug has active patents or pediatric exclusivity relevant to ANDA certification. For a product of DynaCirc CR's age, any historical Orange Book listings are unlikely to create a current entry barrier.
Orange Book status
| Regulatory question |
DynaCirc CR assessment |
| Reference product status |
Historical NDA reference product |
| Active pediatric exclusivity |
None known |
| Current market exclusivity |
None known |
| Active blocking patent strategy |
No material current position identified |
| ANDA pathway |
Available after applicable patent certifications |
| Regulatory risk from biosimilars |
None |
| Regulatory risk from generics |
High, but largely realized |
A current Orange Book review should distinguish between the historical NDA, discontinued marketing status, and any active generic listings. A product may remain listed in FDA databases even after commercial withdrawal.
Which companies have challenged or competed with DynaCirc CR?
The relevant competitive pressure has come from both generic nisoldipine manufacturers and therapeutic substitutes. The second category is more important commercially because physicians can choose from multiple low-cost antihypertensive agents with extensive clinical use.
Direct generic competition
Generic competition can include manufacturers of nisoldipine extended-release tablets in the same strengths and dosage form. Depending on market availability, generic supply may be intermittent because the market is small and manufacturers have limited incentive to maintain multiple suppliers.
The key economic distinction is that a small generic market can experience low prices without stable availability. Manufacturers may discontinue production if sales do not cover manufacturing, quality, inventory, and regulatory costs.
Therapeutic competition
DynaCirc CR competes with:
- Amlodipine, the dominant dihydropyridine calcium-channel blocker
- Felodipine extended release
- Nifedipine extended release
- Isradipine
- Angiotensin-converting enzyme inhibitors
- Angiotensin receptor blockers
- Thiazide diuretics
- Fixed-dose antihypertensive combinations
Amlodipine has a stronger modern prescribing position because of broad generic availability, extensive clinical familiarity, once-daily dosing, and favorable formulary economics. DynaCirc CR has no significant clinical or pricing advantage capable of offsetting that competitive gap.
How does DynaCirc CR compare with competing calcium-channel blockers?
DynaCirc CR is commercially weaker than amlodipine and nifedipine ER because those products have larger prescriber bases and broader generic supply.
| Product |
Active ingredient |
Formulation |
Competitive position |
| DynaCirc CR |
Nisoldipine |
Extended release |
Niche, mature, low commercial relevance |
| Norvasc generic |
Amlodipine |
Immediate release, once daily |
Dominant generic category |
| Plendil generic |
Felodipine |
Extended release |
Established but smaller niche |
| Procardia XL generic |
Nifedipine |
Extended release |
Large historical and current generic category |
| Isradipine generic |
Isradipine |
Immediate or extended formulations |
Limited use |
| Thiazide generics |
Various |
Immediate or extended formulations |
Strong guideline and formulary competition |
DynaCirc CR's extended-release profile is not sufficient to create differentiation because once-daily dosing is common across competing antihypertensive therapies.
What is the financial trajectory of DynaCirc CR?
DynaCirc CR's financial trajectory is a long-term revenue decline followed by low-value residual sales, intermittent generic availability, or commercial discontinuation. No major pharmaceutical company has publicly disclosed a standalone revenue line for DynaCirc CR in recent annual reports.
Revenue trajectory
| Period |
Financial profile |
| Initial branded period |
Revenue supported by branded pricing and physician adoption |
| Early generic period |
Sharp price erosion and loss of market share |
| Mature generic period |
Low unit economics and limited supplier participation |
| Current period |
No identifiable high-growth opportunity; possible residual or discontinued sales |
The absence of product-level revenue disclosure is itself relevant. DynaCirc CR is not material enough to be separately reported by large public pharmaceutical companies. It is likely included in broader categories such as legacy products, established brands, regional pharmaceuticals, or discontinued products.
Main drivers of financial decline
Generic substitution
Once generic nisoldipine ER became available, pharmacy benefit managers and insurers had little reason to reimburse the branded product at a premium. Automatic substitution and formulary controls reduced branded prescription volume.
Therapeutic substitution
Prescribers can select amlodipine, felodipine ER, nifedipine ER, or non-calcium-channel-blocker therapies. This limits the ability of a nisoldipine product to recover pricing through brand positioning.
Small addressable market
Nisoldipine has a smaller installed base than amlodipine and nifedipine. Lower demand reduces manufacturing scale and increases the risk that suppliers withdraw.
Limited lifecycle management
There is no widely recognized next-generation DynaCirc CR franchise, combination product, pediatric expansion, or specialty indication that could support a new revenue cycle.
Distribution economics
Low-volume legacy products face higher per-unit costs for packaging, inventory, pharmacovigilance, quality systems, and regulatory maintenance. These costs can make continued marketing unattractive even when clinical demand persists.
What generic entry risks exist for DynaCirc CR?
The principal generic-entry risk is largely historical rather than pending. DynaCirc CR does not present the profile of a branded product facing a future first generic launch. The market has already moved beyond the central patent-defense period.
Generic launch scenarios
| Scenario |
Probability profile |
Market effect |
| Additional generic entrant |
Possible if supply economics support entry |
Further price pressure, limited volume expansion |
| Branded recovery |
Low |
Requires clinically meaningful differentiation not currently evident |
| Generic supply contraction |
Possible |
Temporary shortages or higher prices despite weak demand |
| Product discontinuation |
Plausible |
Market shifts to other antihypertensive therapies |
| Litigation-driven delay |
Low |
No material active patent dispute is apparent |
The main commercial risk is not a high-value patent challenge. It is erosion of demand, supply rationalization, and substitution into better-established therapies.
What patent litigation affects DynaCirc CR?
No material current patent litigation involving DynaCirc CR is widely reported. The product's age, expired exclusivity, and limited market value reduce the economic rationale for Paragraph IV litigation or large-scale settlement agreements.
Paragraph IV exposure
A generic applicant could historically have used:
- Paragraph IV certification against an Orange Book-listed patent
- Paragraph III certification if waiting for patent expiry
- Section viii statement for non-patented uses
- ANDA approval after patent and exclusivity barriers ended
For DynaCirc CR, any historical Paragraph IV dispute would have been tied to formulation or dosage-form patents. The product does not appear to have a current litigation profile comparable to protected oncology, immunology, diabetes, or specialty cardiovascular products.
Settlement agreements
No major publicly documented reverse-payment settlement is associated with DynaCirc CR. The low expected value of the market would have limited the incentive for a costly, prolonged branded-generic settlement.
What is the biosimilar risk for DynaCirc CR?
DynaCirc CR has no biosimilar risk because nisoldipine is a small-molecule drug, not a biologic. Competition proceeds through the generic-drug pathway, principally ANDAs, rather than the Biologics Price Competition and Innovation Act pathway.
The relevant regulatory risks are:
- Generic ANDA approval
- Therapeutic substitution
- Formulary exclusion
- Product discontinuation
- Manufacturing concentration
- Drug-shortage exposure
How strong is the DynaCirc CR patent estate?
The current patent estate is weak from a commercial perspective. Historical composition and formulation rights may have supported the original franchise, but they do not appear to provide present-day exclusivity.
| Patent-strength factor |
Assessment |
| Remaining composition-of-matter protection |
None expected |
| Remaining formulation protection |
No material active barrier identified |
| Method-of-use protection |
No material current protection identified |
| Manufacturing barriers |
Low to moderate; primarily operational |
| Design-around difficulty |
Low to moderate |
| Litigation value |
Low |
| Ability to support premium pricing |
Minimal |
The product's defensibility is therefore based on regulatory status, supply continuity, and residual brand recognition rather than patent claims.
What licensing deals affected DynaCirc CR?
DynaCirc CR was developed and commercialized through legacy pharmaceutical-company arrangements, but no current licensing transaction has created a meaningful growth platform around the product.
For products of this age, rights can change through:
- Regional licensing
- Portfolio divestitures
- Acquisition of established brands
- Transfers of marketing authorizations
- Contract manufacturing arrangements
These transactions generally transfer a declining revenue stream rather than create new exclusivity. Any current ownership or marketing-rights determination should rely on FDA databases, company product catalogs, and corporate transaction filings rather than historical developer information alone.
What geographic markets remain relevant?
The United States is the most important patent and regulatory jurisdiction because the FDA approval, Orange Book listing, ANDA pathway, and U.S. generic substitution rules determine the principal commercial framework.
Potentially relevant jurisdictions include:
- United States
- Canada
- European Union
- Japan
- Selected Latin American markets
- Other countries where nisoldipine remains registered or supplied
Patent expiry and marketing status vary by country. A product can be commercially discontinued in the United States while remaining available in another market, or it can remain listed in a national database without active distribution.
The global opportunity is limited by the same factors affecting the U.S. market: mature hypertension therapy, generic price competition, and strong substitution by amlodipine and other established agents.
What is the investment and licensing outlook for DynaCirc CR?
DynaCirc CR is unlikely to support a conventional branded-pharmaceutical investment thesis. Its value would be limited to specialized situations such as:
- Acquisition of a low-cost legacy portfolio
- Regional commercialization where supply is constrained
- Manufacturing or API arbitrage
- Portfolio consolidation by a generic company
- Temporary scarcity pricing
- Use as a small component of a broader established-products platform
The product is not an attractive target for a patent-driven licensing strategy. There is no evident remaining exclusivity window, no biosimilar barrier, and no clear indication expansion capable of producing substantial revenue growth.
Key Takeaways
- DynaCirc CR is the extended-release nisoldipine formulation used for hypertension.
- Its original regulatory and patent exclusivity expired many years ago.
- The product faces generic nisoldipine competition and extensive therapeutic substitution.
- Amlodipine, nifedipine ER, felodipine ER, and non-calcium-channel-blocker therapies have stronger commercial positions.
- No material current Paragraph IV litigation or settlement activity is apparent.
- DynaCirc CR has no biosimilar exposure because nisoldipine is a small molecule.
- Public companies do not appear to report standalone DynaCirc CR revenue.
- The financial trajectory is consistent with branded revenue erosion, generic commoditization, and possible residual or discontinued sales.
- Any remaining value is more likely to come from supply continuity or regional portfolio economics than from patents.
FAQs
Is DynaCirc CR still marketed in the United States?
DynaCirc CR has a limited and uncertain current U.S. commercial presence compared with its historical branded period. FDA listing status should be distinguished from active commercial distribution.
Is generic nisoldipine ER available?
Generic nisoldipine extended-release availability can vary by manufacturer, strength, and time period. Small legacy markets may have intermittent supply even after patents expire.
Does DynaCirc CR have an active Orange Book patent?
No material active patent barrier is identified for DynaCirc CR. Historical listings and current Orange Book status should be reviewed separately because database presence does not establish active commercial protection.
Could DynaCirc CR receive a new indication?
A new indication would require clinical development and FDA approval. No current development program or indication-expansion strategy is publicly associated with the product.
Is DynaCirc CR more valuable than amlodipine for licensing?
No. Amlodipine has a substantially larger prescriber base, stronger generic supply, and greater commercial relevance. DynaCirc CR could have niche regional value, but it lacks the market scale and exclusivity profile needed for a comparable licensing thesis.
References
-
U.S. Food and Drug Administration. (1995). DynaCirc CR (nisoldipine) extended-release tablets prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
-
U.S. Food and Drug Administration. (2017). Abbreviated new drug application approvals and patent certifications. FDA.
-
National Library of Medicine. (n.d.). Nisoldipine drug information. DailyMed.
